X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Harmony gets the opportunity to advance the development of a treatment for the symptoms of Fragile X syndrome and other rare neuropsychiatric disorders including, Zygel, the first and only pharmaceutically manufactured, synthetic cannabidiol.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harmony Biosciences
Deal Size: $200.0 million Upfront Cash: $200.0 million
Deal Type: Acquisition October 11, 2023
Details:
Through the acquisition, Harmony gets the opportunity to advance the development of a treatment for the symptoms of Fragile X syndrome and other rare neuropsychiatric disorders including, Zygel, the first and only pharmaceutically manufactured, synthetic cannabidiol.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harmony Biosciences
Deal Size: $200.0 million Upfront Cash: $200.0 million
Deal Type: Acquisition August 14, 2023
Details:
Zygel is the only pharmaceutically-manufactured cannabidiol formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery transdermally. Zygel has the potential for the treatment of Fragile X syndrome symptoms.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Zygel is the first and only pharmaceutically-manufactured cannabidiol formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin).
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Zygel is the first and only pharmaceutically-manufactured cannabidiol formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e., through the skin).
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Zygel is the first and only pharmaceutically-manufactured cannabidiol formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin).
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
Zygel is the first and only pharmaceutically-manufactured cannabidiol formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin).
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Zygel is the first and only pharmaceutically-manufactured cannabidiol formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin).
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
INSPIRE trial for Zygel (Cannabidiol), in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Zynerba intends to use any net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including research and development expenses and capital expenditures.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lincoln Park Capital Fund
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
